— Sanofi (NASDAQ: SNY) reported net loss of EUR 10 million or EUR 0.01 per share for the fourth quarter of 2019, on IFRS basis, down 103.9.% and 105% respectively, from fourth quarter of 2018.
— Business EPS, a non-GAAP measure, grew 17% at constant exchange rates to EUR 1.34.
— IFRS net sales, on a reported basis, increased 6.8% year-over-year to EUR 9.61 billion.
— Sanofi Genzyme sales rose 19.7% annually, aided by strong growth of 135% in Dupixent global sales.
— Vaccine sales increased 22%, reflecting majority of U.S. influenza vaccine shipments in Q4.
— CHC sales down 5.2%, mainly due to Zantac voluntary recall, non-core divestments and changing regulatory requirements.
— For FY20, Sanofi expects business EPS to grow about 5%, at constant exchange rates.
— SNY stock was up about 4% in the pre-market trading session.
Most Popular
Adobe (ADBE) Q2 adjusted earnings rise on higher revenues
Adobe Inc. (NASDAQ: ADBE) on Thursday reported an increase in revenue and adjusted profit for the second quarter of 2025, amid continued growth in its subscription-based business. The design software
ORCL Earnings: Highlights of Oracle’s Q4 2025 financial report
Technology giant Oracle Corporation (NYSE: ORCL) has reported higher revenues and adjusted earnings for the fourth quarter of 2025. Total revenues increased to $15.9 billion in the May quarter from
Key highlights from Chewy’s (CHWY) Q1 2025 earnings results
Chewy, Inc. (NYSE: CHWY) reported its first quarter 2025 earnings results today. Net sales of $3.12 billion increased 8.3% year-over-year. Net income decreased 6.7% to $62.4 million compared to last
